OTLK - Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday? | Benzinga
Outlook Therapeutics Inc (NASDAQ:OTLK) shares are trading higher after the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion concerning the authorization of ONS-5010/LYTENAVA (bevacizumab gamma) for wet age-related macular degeneration (wet AMD).
The shares are trading higher on a strong session volume of 4.485 million compared to an average volume of 160.790K, as per data from Benzinga Pro.
Outlook Therapeutics is assessing both direct commercialization ...